Kymera Therapeutics Inc 2026年季度报告

(Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from ___________________ to ___________________Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. 81-2992166(I.R.S. EmployerIdentification No.) 500 North Beacon Street, 4th FloorWatertown, Massachusetts(Address of principal executive offices) Registrant’s telephone number, including area code: (857) 285-5300 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☐Emerging growth company☐ Large accelerated filer☒Non-accelerated filer☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of April 24, 2026, the registrant had 82,257,588 shares of common stock, $0.0001 par value per share, outstanding. SUMMARY OF THE MATERIAL AND OTHER RISKS ASSOCIATED WITH OUR BUSINESS i•We are a clinical stage company and that may make it difficult for our stockholders to evaluate the success of ourbusiness to date and to assess our future viability.•We have incurred significant operating losses since our inception and anticipate that we will incur continued losses forthe foreseeable future.•We will need to raise substantial additional funding. If we are unable to raise capital when needed or on attractiveterms, we would be forced to delay, scale back or discontinue some of our product candidate development programs orfuture commercialization efforts.•We are very early in our development efforts and our product candidates, whether conducted by us or our collaborators,are in early clinical development. If we are unable to advance them through the clinic for safety or efficacy reasons orcommercialize our product candidates or experience significant delays in doing so, our business will be materiallyharmed.•Our approach to the discovery and development of product candidates is novel and unproven, which makes it difficultto predict the time, cost of development and likelihood of successfully developing any products.•We may not be successful in our efforts to identify or discover additional product candidates, or we may expend ourlimited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates orindications that may be more profitable or for which there is a greater likelihood of success.•If we experience delays or difficulties in the initiation or enrollment of patients in clinical trials, our receipt of necessaryregulatory approvals could be delayed or prevented.•Positive results from early preclinical studies and clinical trials of our current or future product candidates are notnecessarily predictive of the results of later preclinical studies and clinical trials of our current or future productcandidates. If we cannot replicate the positive results from our preclinical studies of our current or future productcandidates in our future clinical trials, we may be unable to successfully develop, obtain regulatory approval for andcommercialize our current or future product candidates.•A pandemic, epidemic, or outbreak of an infectious disease may materially and adversely affect our business and ourfinancial results and could cause a disruption to the development of our product candidates.•Our current or future product candidates may cause adverse or other undesirable side effects that could delay or preventtheir regulatory approval, limit the commercial profile of an approved label, or result in significant negativeconsequences following marketing